

**ASX Announcement | 27 October 2022  
Vioneering Technologies (ASX:VTI)**

## Results of Special Meeting of Stockholders

### Highlights:

- Shareholders approve proposed amendment to convertible note reducing near-term cash needs by US\$1.7 million
- Thorney increases equity holdings in VTI as an endorsement of recent performance and overall corporate strategy

**Atlanta, Georgia, USA Wednesday, 26 October 2022 (Sydney Thursday, 27 October 2022):** US-based medical device company and producer of the NaturalVue® Multifocal 1 Day Contact Lenses, [Vioneering Technologies, Inc. \(ASX:VTI\)](#) ('Vioneering', 'VTI' or 'the Company') announces the results of its Special Meeting of Stockholders held today to vote on a proposed amendment of its Convertible Notes. The results of the meeting are set out in the table below in accordance with ASX Listing Rule 3.13.2.

The sole resolution was decided by way of a poll, with the resolution being passed.

### **Holder Voting Summary**

Shares Issued and Outstanding:	24,601,494	The aggregate number of securities for which proxy votes were received prior to the meeting and for the resolution were the same as the aggregate number of securities voted on the poll.
Shares Voted:	13,838,039	
Shares Voted (%):	56.2%	The resolution was decided by a poll.

Resolution	Vote Type	Voted #	Voted %	Result
Item 1. Approval of variation of Convertible Notes	For	7,890,586	57.0%	Carried
	Against	30,265	0.2%	
	Abstain	5,917,188	42.8%	

The Company has 2,800,000 of Convertible Notes on issue with a face value of US\$1.00 each. Subject to this approval from stockholders, the Company agreed with the holders of the Convertible Notes to amend the terms such that sixty percent (60%) of the notes will convert to CDIs at a conversion price of A\$0.39. The remaining forty percent (40%) of the notes will be amended to set the conversion price at A\$0.60, lower the interest rate from 10% per annum to 8% per annum, and extend the maturity date from 11 July 2023 to 30 June 2024.

The amended conversion prices represent meaningful premiums to the trading price at the time the parties agreed to amend the Convertible Notes. The proposed conversion and change in interest rate will save the Company approximately US\$1.7 million through the current maturity date in July 2023 and will extend the maturity date for the remaining notes to June 2024. These changes will improve the Company's short term cash flow and allow additional time for the Company's operating results to improve and for its trading price to appreciate.

VTI non-executive Chairman David J. Mazzo, Ph.D. said: “The approval of this proposal by our shareholders dramatically reduces VTI’s short-term cash needs while, importantly, demonstrating the confidence of our largest shareholder, Thorney Investment Group, in our overall corporate strategy and performance as it allows them to increase their equity holdings in the company measurably. This agreement follows the third quarter performance in which VTI lowered net cash used in operations by over 60% from both the prior quarter and the same quarter in the prior year. With the added cash runway that this agreement provides and the near complete enrollment in the PROTECT Clinical Study, we remain on track to deliver 1-year trial results by the end of 2023 and to reach cash flow breakeven without the need for an additional capital raise.”

## Ends

This release was authorized by the COO and CFO, Brian Lane.

For more information, please contact:

<b>Company</b>	<b>Investor and media relations</b>
Brian Lane COO and CFO, Visioneering Technologies, Inc. Email: <a href="mailto:blane@vtivision.com">blane@vtivision.com</a>	Haley Chartres H^CK Tel: +61 423 139 163 Email: <a href="mailto:haley@hck.digital">haley@hck.digital</a>

## About Visioneering Technologies

Visioneering Technologies Inc. (ASX:VTI) is an innovative eye care company committed to redefining vision. A pioneer in myopia management, VTI merges advanced engineering with a relentless drive to achieve superior results for patients and practitioners. VTI’s flagship product is the NaturalVue® (etafilcon A) Multifocal 1-Day Contact Lens, an extended depth of focus lens that is one of the most significant innovations in the eye care industry in more than 20 years. For more information, please visit [www.vtivision.com](http://www.vtivision.com) or call +1 844-884-5367, ext. 104.

## Foreign ownership restrictions

VTI’s CHES Depositary Interests (**CDIs**) are issued in reliance on the exemption from registration contained in Regulation S of the US Securities Act of 1933 (**Securities Act**) for offers that are made outside the US. Accordingly, the CDIs have not been, and will not be, registered under the Securities Act or the laws of any state or other jurisdiction in the US. As a result of relying on the Regulation S exemption, the CDIs are ‘restricted securities’ under Rule 144 of the Securities Act. This means that you are unable to sell the CDIs into the US or to a US person for the foreseeable future except in very limited circumstances after the expiration of a restricted period, unless the re-sale of the CDIs is registered under the Securities Act, or an exemption is available. To enforce the above transfer restrictions, all CDIs issued bear a ‘FOR US’ designation on the Australian Securities Exchange (**ASX**). This designation restricts any CDIs from being sold on ASX to US persons. However, you are still able to freely transfer your CDIs on ASX to any person other than a US person. In addition, hedging transactions with regard to the CDIs may only be conducted in accordance with the Securities Act.

### **Forward-Looking Statements**

This announcement contains or may contain forward-looking statements that are based on management's beliefs, assumptions and expectations and on information currently available to management.

All statements that address operating performance, events or developments that we expect or anticipate will occur in the future are forward-looking statements. These include, without limitation, U.S. commercial market acceptance and U.S. sales of our product, as well as our expectations with respect to our ability to develop and commercialize new products.

Given the current uncertainties regarding the on-going impact of COVID-19 on the trading conditions impacting VTI, the financial markets and the health services world-wide, there can be no assurance that future developments will be in accordance with VTI's expectations or that the effect of future developments on VTI will be those anticipated.

Management believes that these forward-looking statements are reasonable when made. You should not place undue reliance on forward-looking statements because they speak only as of the date when made. VTI does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. VTI may not actually achieve the plans, projections or expectations disclosed in forward-looking statements. Actual results, developments or events could differ materially from those disclosed in the forward-looking statements.

VTI-IR-ASX71